Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.43 |
| ▸ | PDE4A | P27815 | 9/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969199 | 0.94 | MET (0.41) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14969211 | 0.90 | MET (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16459841 | 0.80 | MET (0.30) | MET | |
| SCHEMBL14969113 | 0.78 | MAPK1 (0.40) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL17427446 | 0.76 | MET (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16116321 | 0.74 | ALDH1A1 (0.43) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL14969080 | 0.74 | CFTR (0.39) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14969278 | 0.74 | MET (0.38) | ALDH1A1POLBMETTP53ADORA3 | |
| SCHEMBL14969069 | 0.73 | CYP3A4 (0.42) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL14969224 | 0.73 | ADORA2B (0.41) | METTP53ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA, INC. (US) | 2017-11-09 | — | — | US | disclosed |
| US-9745283-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9522902-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-3045453-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9120778-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | PDE5A 3479/4885PDE4A 2382/4885PDE4B 2323/4885 |
| US-20170050949-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | PDE5A 3479/4885PDE4A 2382/4885PDE4B 2323/4885 |
| US-20170320853-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, FLT3 | PDE5A 2996/4885PDE4A 1993/4885PDE4B 1906/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | PDE5A 3479/4885PDE4A 2382/4885PDE4B 2323/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | PDE5A 2996/4885PDE4A 1993/4885PDE4B 1906/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | PDE5A 3479/4885PDE4A 2382/4885PDE4B 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.